Navigation Links
Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.
Date:12/22/2009

HULL, England and FT. SASKATCHEWAN, Canada, Dec. 22 /PRNewswire-FirstCall/ -- The Advanced Wound Management division of Smith & Nephew plc (LSE: SN; NYSE: SNN), announced today that its affiliates have completed the acquisition of substantially all of the assets of Nucryst Pharmaceuticals Corp. ("Nucryst") (Nasdaq: NCST; TSX: NCS). The acquisition includes the manufacturing assets from Nucryst's Fort Saskatchewan, Canada operations and the intellectual property estate.

Since 2001, Smith & Nephew has held exclusive license for the sale of the ACTICOAT(TM) dressing portfolio, manufactured at the Ft. Saskatchewan site. This acquisition gives Advanced Wound Management full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in ACTICOAT, which is the second largest brand in the Smith & Nephew Advanced Wound Management product portfolio.

"The ACTICOAT dressings are the only products on the market using the proprietary antimicrobial nanocrystalline silver technology known as SILCRYST(TM). Acquiring this technology and the manufacturing capabilities behind it underlines our commitment to bring clinicians and patients the most advanced solutions for their wound care needs," said Roger Teasdale, President, Advanced Wound Management.


    Enquiries

    Investors
    Liz Hewitt                                       Tel: +44 (0) 20 7401 7646
    Smith & Nephew
    Group Director Corporate Affairs

    Phil Cowdy                                       Tel: +44 (0) 20 7401 7646
    Smith & Nephew
    Director - Investor Relations

    Other Inquiries
    Roger Teasdale                                   Tel: +44 (0) 14 8267 3905
    President, Advanced Wound Management

    Media
    Jon Coles                                        Tel: +44 (0) 20 7404 5959
    Brunswick - London

    Katie Cralle                                     Tel: +1 (212) 333 3810
    Brunswick - New York

About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew plc


'/>"/>
SOURCE Smith & Nephew plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
2. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
3. Upsher-Smith Announces Milestone in Development of CNS Strategy
4. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
5. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
6. Arcadia Resources Names Stephen Goldsmith to Board of Directors
7. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
8. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
9. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
10. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
11. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a church ... “They Sang At Her Funeral” is the creation of published author, Annalise Harold, an ... and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... , ... September 19, 2017 ... ... that Scott McFarland has joined its executive team as the President of ... innovative value-based care management systems and contact centers. , “Scott is a ...
Breaking Medicine News(10 mins):